205 related articles for article (PubMed ID: 34021724)
1. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
Rameez S; Gowtham YK; Nayar G; Mostafa SS
Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
[TBL] [Abstract][Full Text] [Related]
2. A class of low-cost alternatives to kifunensine for increasing high mannose N-linked glycosylation for monoclonal antibody production in Chinese hamster ovary cells.
Brantley TJ; Mitchelson FG; Khattak SF
Biotechnol Prog; 2021 Jan; 37(1):e3076. PubMed ID: 32888259
[TBL] [Abstract][Full Text] [Related]
3. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
4. Monensin, a small molecule ionophore, can be used to increase high mannose levels on monoclonal antibodies generated by Chinese hamster ovary production cell-lines.
Pande S; Rahardjo A; Livingston B; Mujacic M
Biotechnol Bioeng; 2015 Jul; 112(7):1383-94. PubMed ID: 25619381
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans.
Shi HH; Goudar CT
Biotechnol Bioeng; 2014 Oct; 111(10):1907-19. PubMed ID: 24975601
[TBL] [Abstract][Full Text] [Related]
6. Effects of cell culture conditions on antibody N-linked glycosylation--what affects high mannose 5 glycoform.
Pacis E; Yu M; Autsen J; Bayer R; Li F
Biotechnol Bioeng; 2011 Oct; 108(10):2348-58. PubMed ID: 21557201
[TBL] [Abstract][Full Text] [Related]
7. The Formidable Challenge of Controlling High Mannose-Type N-Glycans in Therapeutic mAbs.
Mastrangeli R; Audino MC; Palinsky W; Broly H; Bierau H
Trends Biotechnol; 2020 Oct; 38(10):1154-1168. PubMed ID: 32616303
[TBL] [Abstract][Full Text] [Related]
8. Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.
Borza B; Szigeti M; Szekrenyes A; Hajba L; Guttman A
J Pharm Biomed Anal; 2018 May; 153():182-185. PubMed ID: 29499461
[TBL] [Abstract][Full Text] [Related]
9. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
10. Cell culture media supplemented with raffinose reproducibly enhances high mannose glycan formation.
Brühlmann D; Muhr A; Parker R; Vuillemin T; Bucsella B; Kalman F; Torre S; La Neve F; Lembo A; Haas T; Sauer M; Souquet J; Broly H; Hemberger J; Jordan M
J Biotechnol; 2017 Jun; 252():32-42. PubMed ID: 28465212
[TBL] [Abstract][Full Text] [Related]
11. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
[TBL] [Abstract][Full Text] [Related]
12. Control of therapeutic IgG antibodies galactosylation during cultivation process and its impact on IgG1/FcγR interaction and ADCC activity.
Simonov V; Ivanov S; Smolov M; Abbasova S; Piskunov A; Poteryaev D
Biologicals; 2019 Mar; 58():16-21. PubMed ID: 30655169
[TBL] [Abstract][Full Text] [Related]
13. A robust method for increasing Fc glycan high mannose level of recombinant antibodies.
Huang CJ; Lin H; Yang JX
Biotechnol Bioeng; 2015 Jun; 112(6):1200-9. PubMed ID: 25565276
[TBL] [Abstract][Full Text] [Related]
14. Metabolic markers associated with high mannose glycan levels of therapeutic recombinant monoclonal antibodies.
Kang S; Zhang Z; Richardson J; Shah B; Gupta S; Huang CJ; Qiu J; Le N; Lin H; Bondarenko PV
J Biotechnol; 2015 Jun; 203():22-31. PubMed ID: 25797592
[TBL] [Abstract][Full Text] [Related]
15. Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation.
Fan Y; Jimenez Del Val I; Müller C; Wagtberg Sen J; Rasmussen SK; Kontoravdi C; Weilguny D; Andersen MR
Biotechnol Bioeng; 2015 Mar; 112(3):521-35. PubMed ID: 25220616
[TBL] [Abstract][Full Text] [Related]
16. Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.
Dorvignit D; Palacios JL; Merino M; Hernández T; Sosa K; Casaco A; López-Requena A; Mateo de Acosta C
MAbs; 2012; 4(4):488-96. PubMed ID: 22647435
[TBL] [Abstract][Full Text] [Related]
17. Different fermentation processes produced variants of an anti-CD52 monoclonal antibody that have divergent in vitro and in vivo characteristics.
Zhuang C; Zheng C; Chen Y; Huang Z; Wang Y; Fu Q; Zeng C; Wu T; Yang L; Qi N
Appl Microbiol Biotechnol; 2017 Aug; 101(15):5997-6006. PubMed ID: 28512676
[TBL] [Abstract][Full Text] [Related]
18. Interaction of cell culture process parameters for modulating mAb afucosylation.
Nguyen Dang A; Mun M; Rose CM; Ahyow P; Meier A; Sandoval W; Yuk IH
Biotechnol Bioeng; 2019 Apr; 116(4):831-845. PubMed ID: 30597531
[TBL] [Abstract][Full Text] [Related]
19. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
[TBL] [Abstract][Full Text] [Related]
20. An efficient method to control high mannose and core fucose levels in glycosylated antibody production using deoxymannojirimycin.
Shalel Levanon S; Aharonovitz O; Maor-Shoshani A; Abraham G; Kenett D; Aloni Y
J Biotechnol; 2018 Jun; 276-277():54-62. PubMed ID: 29673624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
